Report #2890873

Received Mar 26, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: NJ
Recovered: Unknown
Vaccinated: Mar 10, 2026
Onset: Mar 10, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
MNQ	MENINGOCOCCAL CONJUGATE (MENVEO)	NOVARTIS VACCINES AND DIAGNOSTICS	2	7742A	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Less than recommended interval; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a patient who received Men ACWY-CRM NVS (Menveo) (batch number 7742A, expiry date 31-JAN-2027) for prophylaxis. Previously administered products included Menveo (received 1st dose on 27-FEB-2025). On 10-MAR-2026, the patient received the 2nd dose of Menveo. On 10-MAR-2026, an unknown time after receiving Menveo, the patient experienced drug dose administration interval too short (Verbatim: Less than recommended interval). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 11-MAR-2026 The vaccine administration facility was the same as primary reporter.